Cargando…
Phase II study of induction chemotherapy with TPF followed by radioimmunotherapy with Cetuximab and intensity-modulated radiotherapy (IMRT) in combination with a carbon ion boost for locally advanced tumours of the oro-, hypopharynx and larynx - TPF-C-HIT
BACKGROUND: Long-term locoregional control in locally advanced squamous cell carcinoma of the head and neck (SCCHN) remains challenging. While recent years have seen various approaches to improve outcome by intensification of treatment schedules through introduction of novel induction and combinatio...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3118195/ https://www.ncbi.nlm.nih.gov/pubmed/21595970 http://dx.doi.org/10.1186/1471-2407-11-182 |
_version_ | 1782206434663989248 |
---|---|
author | Jensen, Alexandra D Krauss, Jürgen Potthoff, Karin Desta, Almaz Habl, Gregor Mavtratzas, Athanasios Windemuth-Kiesselbach, Christine Debus, Jürgen Münter, Marc W |
author_facet | Jensen, Alexandra D Krauss, Jürgen Potthoff, Karin Desta, Almaz Habl, Gregor Mavtratzas, Athanasios Windemuth-Kiesselbach, Christine Debus, Jürgen Münter, Marc W |
author_sort | Jensen, Alexandra D |
collection | PubMed |
description | BACKGROUND: Long-term locoregional control in locally advanced squamous cell carcinoma of the head and neck (SCCHN) remains challenging. While recent years have seen various approaches to improve outcome by intensification of treatment schedules through introduction of novel induction and combination chemotherapy regimen and altered fractionation regimen, patient tolerance to higher treatment intensities is limited by accompanying side-effects. Combined radioimmunotherapy with cetuximab as well as modern radiotherapy techniques such as intensity-modulated radiotherapy (IMRT) and carbon ion therapy (C12) are able to limit toxicity while maintaining treatment effects. In order to achieve maximum efficacy with yet acceptable toxicity, this sequential phase II trial combines induction chemotherapy with docetaxel, cisplatin, and 5-FU (TPF) followed by radioimmunotherapy with cetuximab as IMRT plus carbon ion boost. We expect this approach to result in increased cure rates with yet manageable accompanying toxicity. METHODS/DESIGN: The TPF-C-HIT trial is a prospective, mono-centric, open-label, non-randomized phase II trial evaluating efficacy and toxicity of the combined treatment with IMRT/carbon ion boost and weekly cetuximab in 50 patients with histologically proven locally advanced SCCHN following TPF induction chemotherapy. Patients receive 24 GyE carbon ions (8 fractions) and 50 Gy IMRT (2.0 Gy/fraction) in combination with weekly cetuximab throughout radiotherapy. Primary endpoint is locoregional control at 12 months, secondary endpoints are disease-free survival, progression-free survival, overall survival, acute and late radiation effects as well as any adverse events of the treatment as well as quality of life (QoL) analyses. DISCUSSION: The primary objective of TPF-C-HIT is to evaluate efficacy and toxicity of cetuximab in combination with combined IMRT/carbon ion therapy following TPF induction in locally advanced SCCHN. TRIAL REGISTRATION: Clinical Trial Identifier: NCT01245985 (clinicaltrials.gov) EudraCT number: 2009 - 016489- 10 |
format | Online Article Text |
id | pubmed-3118195 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2011 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-31181952011-06-19 Phase II study of induction chemotherapy with TPF followed by radioimmunotherapy with Cetuximab and intensity-modulated radiotherapy (IMRT) in combination with a carbon ion boost for locally advanced tumours of the oro-, hypopharynx and larynx - TPF-C-HIT Jensen, Alexandra D Krauss, Jürgen Potthoff, Karin Desta, Almaz Habl, Gregor Mavtratzas, Athanasios Windemuth-Kiesselbach, Christine Debus, Jürgen Münter, Marc W BMC Cancer Study Protocol BACKGROUND: Long-term locoregional control in locally advanced squamous cell carcinoma of the head and neck (SCCHN) remains challenging. While recent years have seen various approaches to improve outcome by intensification of treatment schedules through introduction of novel induction and combination chemotherapy regimen and altered fractionation regimen, patient tolerance to higher treatment intensities is limited by accompanying side-effects. Combined radioimmunotherapy with cetuximab as well as modern radiotherapy techniques such as intensity-modulated radiotherapy (IMRT) and carbon ion therapy (C12) are able to limit toxicity while maintaining treatment effects. In order to achieve maximum efficacy with yet acceptable toxicity, this sequential phase II trial combines induction chemotherapy with docetaxel, cisplatin, and 5-FU (TPF) followed by radioimmunotherapy with cetuximab as IMRT plus carbon ion boost. We expect this approach to result in increased cure rates with yet manageable accompanying toxicity. METHODS/DESIGN: The TPF-C-HIT trial is a prospective, mono-centric, open-label, non-randomized phase II trial evaluating efficacy and toxicity of the combined treatment with IMRT/carbon ion boost and weekly cetuximab in 50 patients with histologically proven locally advanced SCCHN following TPF induction chemotherapy. Patients receive 24 GyE carbon ions (8 fractions) and 50 Gy IMRT (2.0 Gy/fraction) in combination with weekly cetuximab throughout radiotherapy. Primary endpoint is locoregional control at 12 months, secondary endpoints are disease-free survival, progression-free survival, overall survival, acute and late radiation effects as well as any adverse events of the treatment as well as quality of life (QoL) analyses. DISCUSSION: The primary objective of TPF-C-HIT is to evaluate efficacy and toxicity of cetuximab in combination with combined IMRT/carbon ion therapy following TPF induction in locally advanced SCCHN. TRIAL REGISTRATION: Clinical Trial Identifier: NCT01245985 (clinicaltrials.gov) EudraCT number: 2009 - 016489- 10 BioMed Central 2011-05-19 /pmc/articles/PMC3118195/ /pubmed/21595970 http://dx.doi.org/10.1186/1471-2407-11-182 Text en Copyright ©2011 Jensen et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Study Protocol Jensen, Alexandra D Krauss, Jürgen Potthoff, Karin Desta, Almaz Habl, Gregor Mavtratzas, Athanasios Windemuth-Kiesselbach, Christine Debus, Jürgen Münter, Marc W Phase II study of induction chemotherapy with TPF followed by radioimmunotherapy with Cetuximab and intensity-modulated radiotherapy (IMRT) in combination with a carbon ion boost for locally advanced tumours of the oro-, hypopharynx and larynx - TPF-C-HIT |
title | Phase II study of induction chemotherapy with TPF followed by radioimmunotherapy with Cetuximab and intensity-modulated radiotherapy (IMRT) in combination with a carbon ion boost for locally advanced tumours of the oro-, hypopharynx and larynx - TPF-C-HIT |
title_full | Phase II study of induction chemotherapy with TPF followed by radioimmunotherapy with Cetuximab and intensity-modulated radiotherapy (IMRT) in combination with a carbon ion boost for locally advanced tumours of the oro-, hypopharynx and larynx - TPF-C-HIT |
title_fullStr | Phase II study of induction chemotherapy with TPF followed by radioimmunotherapy with Cetuximab and intensity-modulated radiotherapy (IMRT) in combination with a carbon ion boost for locally advanced tumours of the oro-, hypopharynx and larynx - TPF-C-HIT |
title_full_unstemmed | Phase II study of induction chemotherapy with TPF followed by radioimmunotherapy with Cetuximab and intensity-modulated radiotherapy (IMRT) in combination with a carbon ion boost for locally advanced tumours of the oro-, hypopharynx and larynx - TPF-C-HIT |
title_short | Phase II study of induction chemotherapy with TPF followed by radioimmunotherapy with Cetuximab and intensity-modulated radiotherapy (IMRT) in combination with a carbon ion boost for locally advanced tumours of the oro-, hypopharynx and larynx - TPF-C-HIT |
title_sort | phase ii study of induction chemotherapy with tpf followed by radioimmunotherapy with cetuximab and intensity-modulated radiotherapy (imrt) in combination with a carbon ion boost for locally advanced tumours of the oro-, hypopharynx and larynx - tpf-c-hit |
topic | Study Protocol |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3118195/ https://www.ncbi.nlm.nih.gov/pubmed/21595970 http://dx.doi.org/10.1186/1471-2407-11-182 |
work_keys_str_mv | AT jensenalexandrad phaseiistudyofinductionchemotherapywithtpffollowedbyradioimmunotherapywithcetuximabandintensitymodulatedradiotherapyimrtincombinationwithacarbonionboostforlocallyadvancedtumoursoftheorohypopharynxandlarynxtpfchit AT kraussjurgen phaseiistudyofinductionchemotherapywithtpffollowedbyradioimmunotherapywithcetuximabandintensitymodulatedradiotherapyimrtincombinationwithacarbonionboostforlocallyadvancedtumoursoftheorohypopharynxandlarynxtpfchit AT potthoffkarin phaseiistudyofinductionchemotherapywithtpffollowedbyradioimmunotherapywithcetuximabandintensitymodulatedradiotherapyimrtincombinationwithacarbonionboostforlocallyadvancedtumoursoftheorohypopharynxandlarynxtpfchit AT destaalmaz phaseiistudyofinductionchemotherapywithtpffollowedbyradioimmunotherapywithcetuximabandintensitymodulatedradiotherapyimrtincombinationwithacarbonionboostforlocallyadvancedtumoursoftheorohypopharynxandlarynxtpfchit AT hablgregor phaseiistudyofinductionchemotherapywithtpffollowedbyradioimmunotherapywithcetuximabandintensitymodulatedradiotherapyimrtincombinationwithacarbonionboostforlocallyadvancedtumoursoftheorohypopharynxandlarynxtpfchit AT mavtratzasathanasios phaseiistudyofinductionchemotherapywithtpffollowedbyradioimmunotherapywithcetuximabandintensitymodulatedradiotherapyimrtincombinationwithacarbonionboostforlocallyadvancedtumoursoftheorohypopharynxandlarynxtpfchit AT windemuthkiesselbachchristine phaseiistudyofinductionchemotherapywithtpffollowedbyradioimmunotherapywithcetuximabandintensitymodulatedradiotherapyimrtincombinationwithacarbonionboostforlocallyadvancedtumoursoftheorohypopharynxandlarynxtpfchit AT debusjurgen phaseiistudyofinductionchemotherapywithtpffollowedbyradioimmunotherapywithcetuximabandintensitymodulatedradiotherapyimrtincombinationwithacarbonionboostforlocallyadvancedtumoursoftheorohypopharynxandlarynxtpfchit AT muntermarcw phaseiistudyofinductionchemotherapywithtpffollowedbyradioimmunotherapywithcetuximabandintensitymodulatedradiotherapyimrtincombinationwithacarbonionboostforlocallyadvancedtumoursoftheorohypopharynxandlarynxtpfchit |